Scynexis Wins $214M Contract from Biomedical Advanced Research and Development Authority
SCYNEXIS was awarded a contract from BARDA providing up to $214 million in non-dilutive funding to support the development of SCY-247, a second-generation antifungal candidate. The agreement includes an initial $18.5 million base period to advance the candidate into Phase 2 studies for invasive candidiasis, with subsequent options that could fund the program through NDA submission.
- Value
- $214M
- Counterparty
- Biomedical Advanced Research and Development Authority (BARDA)
- Term
- up to 10 years
“We are proud to partner with BARDA to advance the development of SCY-247, our antifungal designed to address the growing threat of antimicrobial resistance.”
David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS
“While we remain focused on SCY-770, our new product candidate for ADPKD, this partnership enables the development of a novel therapy for the treatment and prevention of serious invasive fungal infections while leveraging our existing infrastructure and capabilities.”
David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS